Sie befinden sich hier: Mitarbeiter > publist

Prof. Dr. med. Axel Hauschild
Aktuelle Publikationen


2017

Keine Einträge

2016

Santiago-Walker A, Gagnon R, Mazumdar J, Casey M, Long GV, Schadendorf D, Flaherty K, Kefford R, Hauschild A, Hwu P, Haney P, O'Hagan A, Carver J, Goodman V, Legos J, Martin AM
Correlation of braf mutation status in circulating-free DNA and tumor and association with clinical outcome across four brafi and meki clinical trials.
Clin. Cancer Res. 2016;22:567-574
Maul LV, Weichenthal M, Kahler K, Hauschild A
Pembrolizumab in an advanced melanoma and immune suppressed patient with a churg-strauss syndrome following ipilimumab-induced colitis.
Oncol Res Treat 2016;39:148-149
Egberts F, Bohne AS, Krüger S, Hedderich J, Rompel R, Haag J, Röcken C, Hauschild A
Varying Mutational Alterations in Multiple Primary Melanomas.
J Mol Diagn 2016;18(1):75-83
Hügel R, Muendlein A, Volbeding L, Drexel H, Richtig E, Wehkamp U, Painsi C, Lange-Asschenfeldt B, Hauschild A, Egberts F.
Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma.
Melanoma Res 2016;26(4):354-60

2015

Gogas H, Abali H, Ascierto PA, Demidov L, Pehamberger H, Robert C, Schachter J, Eggermont AM, Hauschild A, Espinosa E
Who Benefits Most From Adjuvant Interferon Treatment for Melanoma?
Am J Ther. 2015;22(1):54-60
Livingstone E, Eigentler TK, Windemuth-Kieselbach C, Hauschild A, Rompel R, Trefzer U, Nashan D, Kilian K, Debus D, Kähler KC, Mauerer A, Möllenhoff K, Dippel E, Schadendorf D
Actual practice of melanoma follow-up and treatment in Germany: results of a prospective, longitudinal cohort study
Br J Dermatol 2015;172(6):1646-50
Livingstone E, Krajewski C, Eigentler TK, Windemuth-Kieselbach C, Benson S, Elsenbruch S, Hauschild A, Rompel R, Meiss F, Mauerer A, Kähler KC, Dippel E, Möllenhoff K, Kilian K, Mohr P, Utikal J, Schadendorf D
Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicentre and longitudinal study
Eur J Cancer 2015;51(5):653-67
Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D
Improved overall survival in melanoma with combined dabrafenib and trametinib
N Engl J Med. 2015;372(1):30-9
Lorigan P, Ascierto PA, Dummer R, Eggermont AM, Flaherty KT, Garbe C, Gogas H, Hauschild A, Kefford RF, Kirkwood JM, Larkin J, Long GV, Maio M, McArthur GA, Ribas A, Robert C, Schadendorf D, Sondak VK, Wolchok JD, Hudson AM
Expanded access programmes: patient interests versus clinical trial integrity.
Lancet Oncol. 2015;16(1):15-7
Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J, Garbe C, Herbst R, Enk A, Kämpgen E, Livingstone E, Bluhm L, Rompel R, Griewank KG, Fluck M, Schilling B, Schadendorf D
Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
PLoS One 2015;10(3):e0118564
Kaehler KC, Politz O, Henderson D, Ulbrich HF, Hauschild A, Mund C, Egberts F
Novel DNA methylation markers with potential prognostic relevance in advanced malignant melanoma identified using COBRA assays.
Melanoma Res 2015;25(3):225-31
Szeimies RM, Hauschild A, Ortland C, Moor AC, Stocker M, Surber C
Photodynamic therapy simplified: nonprepared, moderate-grade actinic keratosis lesions respond equally well to 5-aminolaevulinic acid patch photodynamic therapy as do mild lesions.
Br J Dermatol 2015;173(5):1277-9
Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Dirix L, Hou J, Yue H, Hauschild A; ERIVANCE BCC investigators
Rationale, Visionen und Grenzen der Immunonkologie: Checkpoint-Inhibition als neue Therapiesäule der Tumortherapie.
J Am Acad Dermatol 2015;72(6):1021-6
Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Jouary T, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Williams S, Fittipaldo A, Xynos I, Hansson J
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
Lancet Oncol. 2015;16(6):729-36
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Swann S, Legos JJ, Jin F, Mookerjee B, Flaherty K
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
Lancet 2015;386(9992):444-51
Hauschild A, Garbe C
Immunotherapy: Combined immunotherapy-a new standard in metastatic melanoma?
Nat Rev Clin Oncol 2015;12(8):439-40
Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U; ESMO Guidelines Committee
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann Oncol 2015;26 Suppl 5:v126-v132.
Maul LV, Kähler KC, Hauschild A.
Effective and Tolerable Treatment of Advanced Basal Cell Carcinoma With Vismodegib Despite Renal Insufficiency.
JAMA Dermatol. 2015 2015;Dec 30
Maul LV, Hofmeister J, Hauschild A, Kähler KC
Anhaltende komplette Remission eines metastasierten malignen Melanoms durch den PD-1-Antikörper Pembrolizumab nach BRAF-Inhibition
Journal der Deutschen Dermatologischen Gesellschaft 2015;13:44
Maul LV, Hauschild A, Kähler KC
Effektive lokale Tumorkontrolle eines kutan metastasierten Angiosarkoms durch Elektrochemotherapie
Journal der Deutschen Dermatologischen Gesellschaft 2015;13: 375
Maul LV, Hauschild A, Kähler KC
Effektive Therapie kutaner Metastasen eines Mammakarzinoms mit Elektrochemotherapie: ein Fallbericht
Journal der Deutschen Dermatologischen Gesellschaft 2015;13:168
Kaehler KC, Augustin M, Blome C, Forschner A, Gutzmer R, Garbe C, Gebhardt C, Heinzerling L, Kornek T, Livingstone E, Loquai C, Maul LV, Rudolph BM, Schadendorf D, Stade B, Terheyden P, Wagner T, Hauschild A
The GERMELATOX DeCOG-trial: Attitude of German melanoma patients towards toxicity during adjuvant interferon treatment - Differences between the patient's and the physician's perspective
J Clin Oncol 2015;suppl; abstr e20099
Mangana J, Cheng PF, Schindler K, Weide B, Held U, Frauchiger AL, Romano E, Kahler KC, Rozati S, Rechsteiner M, Moch H, Michielin O, Garbe C, Hauschild A, Hoeller C, Dummer R, Goldinger SM
Analysis of braf and nras mutation status in advanced melanoma patients treated with anti-ctla-4 antibodies: Association with overall survival?
Plos One 2015;10:e0139438
Dummer R, Schadendorf D, Ascierto PA, Larkin J, Lebbe C, Hauschild A
Integrating first-line treatment options into clinical practice: What's new in advanced melanoma?
Melanoma Res. 2015;25:461-469
Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, McDowell DO, Mookerjee B, Schadendorf D, Robert C
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous braf val600-mutation-positive melanoma (combi-v): Results of a phase 3, open-label, randomised trial.
Lancet Oncol. 2015;16:1389-1398
Zimmer L, Eigentler TK, Kiecker F, Simon J, Utikal J, Mohr P, Berking C, Kampgen E, Dippel E, Stadler R, Hauschild A, Fluck M, Terheyden P, Rompel R, Loquai C, Assi Z, Garbe C, Schadendorf D
Open-label, multicenter, single-arm phase ii decog-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.
J Transl Med. 2015;13:351
Winkelmann RR, Hauschild A, Tucker N, White R, Rigel DS
The impact of multispectral digital skin lesion analysis on german dermatologist decisions to biopsy atypical pigmented lesions with clinical characteristics of melanoma.
J Clin Aesthet Dermatol. 2015;8:27-29
Cierlitza M, Chauvistre H, Bogeski I, Zhang X, Hauschild A, Herlyn M, Schadendorf D, Vogt T, Roesch A
Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations.
Exp. Dermatol. 2015;24:155-157
Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai C, Testori A, Bhatia S, Gutzmer R, Conry R, Haydon A, Robert C, Ernst S, Homsi J, Grob JJ, Kendra K, Agarwala SS, Li M, Clawson A, Brachmann C, Karnoub M, Elias I, Renschler MF, Hauschild A
A randomized, controlled phase iii trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma.
Ann. Oncol. 2015;26:2267-2274
Wainstein A, Algarra SM, Bastholt L, Cinat G, Demidov L, Grob JJ, Guo J, Hersey P, Espinosa E, Schachter J, Whitaker D, Quirt I, Hauschild A, Rutkowski P
Melanoma early detection and awareness: How countries developing melanoma awareness programs could benefit from melanoma-proficient countries.
Am. J.Ther. 2015;22:37-43
Gogas H, Abali H, Ascierto PA, Demidov L, Pehamberger H, Robert C, Schachter J, Eggermont AM, Hauschild A, Espinosa E
Who benefits most from adjuvant interferon treatment for melanoma?
Am. J. ther. 2015;22:54-60
Espinosa E, Grob JJ, Dummer R, Rutkowski P, Robert C, Gogas H, Kefford R, Eggermont AM, Martin Algarra S, Hauschild A, Schadendorf D
Treatment algorithms in stage iv melanoma.
Am. J. Ther. 2015;22:61-67
Ascierto PA, Bastholt L, Hersey P, Cinat G, Eggermont AM, Hauschild A, Espinosa E, Robert C
Side effects and toxicities of targeted therapies in stage IV melanoma.
Am. J. Ther. 2015;22:44-53
Mohr P, Hauschild A, Trefzer U, Enk A, Tilgen W, Loquai C, Gogas H, Haalck T, Koller J, Dummer R, Gutzmer R, Brockmeyer N, Hölzle E, Sunderkötter C, Mauch C, Stein A, Schneider LA, Podda M, Göppner D, Schadendorf D, Weichenthal M.
Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
J Clin Oncol. 2015;33(34):4077-84

2014

Egberts F, Bergner I, Krüger S, Haag J, Behrens HM, Hauschild A, Röcken C.
Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas.
Ann. Oncol. 2014;25(1):246-50
Egberts F, Krüger S, Behrens HM, Bergner I, Papaspyrou G, Werner JA, Alkatout I, Haag J, Hauschild A, Röcken C.
Melanomas of unknown primary frequently harbour TERT-promoter mutations.
Melanoma Res. 2014;24(2):131-6
Koop A, Satzger I, Alter M, Kapp A, Hauschild A, Gutzmer R
Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma.
Br J Dermatol. 2014;170(1):220-2
Ugurel S, Mentzel T, Utikal J, Helmbold P, Mohr P, Pföhler C, Schiller M, Hauschild A, Hein R, Kämpgen E, Kellner I, Leverkus M, Becker JC, Ströbel P, Schadendorf D.
Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
Clin Cancer Res. 2014;20(2):499-510
Goldinger SM, Zimmer L, Schulz C, Ugurel S, Hoeller C, Kaehler KC, Schadendorf D, Hassel JC, Becker J, Hauschild A, Dummer R; Dermatology Cooperative Oncology Group (DeCOG).
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Eur J Cancer 2014;50(2):406-10
McCusker M, Basset-Seguin N, Dummer R, Lewis K, Schadendorf D, Sekulic A, Hou J, Wang L, Yue H, Hauschild A
Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease.
Eur J Cancer 2014;50(4):774-783
Schadendorf D, Hauschild A.
Melanoma in 2013: Melanoma-the run of success continues.
Nat Rev Clin Oncol. 2014;11(2)-75-6
Flaherty KT, Hennig M, Lee SJ, Ascierto PA, Dummer R, Eggermont AM, Hauschild A, Kefford R, Kirkwood JM, Long GV, Lorigan P, Mackensen A, McArthur G, O'Day S, Patel PM, Robert C, Schadendorf D
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials.
Lancet Oncol. 2014;15(3):297-304
McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O'Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A.
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
Lancet Oncol. 2014;15(3):323-32
Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH Jr, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study.
Lancet Oncol. 2014;15(4):436-44
Maul LV, Hauschild A, Kähler KC
Symptomatische Hautmetastasen eines Mammakarzinoms – ein multimodales Therapiekonzept.
JDDG 2014;12(Suppl. 3):31
Erkens AS, Maul LV, Hauschild A, Kähler KC
Sichere und effektive Therapie eines metastasierten Melanoms mit Vemurafenib bei kardialer Komorbidität.
JDDG 2014;12(Suppl.3):17
Hauschild A, Chen SC, Weichenthal M, Blum A, King HC, Goldsmith J, Scharfstein D, Gutkowicz-Krusin D
To excise or not: impact of MelaFind on German dermatologists' decisions to biopsy atypical lesions.
J Dtsch Dermatol Ges 2014;12(7):606-14
Lacouture ME, Wolchok JD, Yosipovitch G, Kähler KC, Busam KJ, Hauschild A
Ipilimumab in patients with cancer and the management of dermatologic adverse events
J Am Acad Dermatol 2014;71(1):161-9
Berking C, Hauschild A, Kölbl O, Mast G, Gutzmer R
Basal cell carcinoma-treatments for the commonest skin cancer
Dtsch Arztebl Int. 2014;111(22):389-95
Kaehler KC, Gutzmer R, Egberts F, Hauschild A
Regression of a basal cell carcinoma infiltrating the brain after vismodegib therapy.
J Dtsch Dermatol Ges 2014;12(10):906-7
Eigentler TK, Schlaak M, Hassel JC, Loquai C, Stoffels I, Gutzmer R, Pätzold S, Mohr P, Keller U, Starz H, Ulrich J, Tsianakas A, Kähler K, Hauschild A, Janssen E, Schuler-Thurner B, Weide B, Garbe C
Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions
J Immunother 2014;37(7):374-81
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Casey M, Ouellet D, Martin AM, Le N, Patel K, Flaherty K
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
N Engl J Med. 2014;371(20):1877-88
Hauschild A, Kölbl O, Mackensen A, Schadendorf D
Forward: anti-tumor immunity and tumor immunology
Oncol Res Treat 2014;37 Suppl 4:1
Hauschild A
Working Group on Dermatological Oncology
J Dtsch Dermatol Ges 2014;12(11):1069-70
Buzaid AC, Agarwala SS, Hauschild A, Atkins M
Algorithm for the management of metastatic cutaneous melanoma.
Chin Clin Oncol. 2014;3(3):32

2013

Degen A, Weichenthal M, Ugurel S, Trefzer U, Kilian K, Garbe C, Egberts F, Poppe LM, Hauschild A, Gutzmer R
Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial)
J Dtsch Dermatol. Ges. 2013;11(9):846-53
Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D, Dippel E, Eigentler T, Feyer P, Follmann M, Frerich B, Ganten MK, Gärtner J, Gutzmer R, Hassel J, Hauschild A, Hohenberger P, Hübner J, Kaatz M, Kleeberg UR, Kölbl O, Kortmann RD, Krause-Bergmann A, Kurschat P, Leiter U, Link H, Loquai C, Löser C, Mackensen A, Meier F, Mohr P, Möhrle M, Nashan D, Reske S, Rose C, Sander C, Satzger I, Schiller M, Schlemmer HP, Strittmatter G, Sunderkötter C, Swoboda L, Trefzer U, Voltz R, Vordermark D, Weichenthal M, Werner A, Wesselmann S, Weyergraf AJ, Wick W, Garbe C, Schadendorf D; German Society of Dermatology.
S3-guideline "diagnosis, therapy and follow-up of melanoma" -- short version
J Dtsch Dermatol Ges 2013;11(6):563-602
Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D, Dippel E, Eigentler T, Feyer P, Follmann M, Frerich B, Ganten MK, Gärtner J, Gutzmer R, Hassel J, Hauschild A, Hohenberger P, Hübner J, Kaatz M, Kleeberg UR, Kölbl O, Kortmann RD, Krause-Bergmann A, Kurschat P, Leiter U, Link H, Loquai C, Löser C, Mackensen A, Meier F, Mohr P, Möhrle M, Nashan D, Reske S, Rose C, Sander C, Satzger I, Schiller M, Schlemmer HP, Strittmatter G, Sunderkötter C, Swoboda L, Trefzer U, Voltz R, Vordermark D, Weichenthal M, Werner A, Wesselmann S, Weyergraf AJ, Wick W, Garbe C, Schadendorf D.
Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma".
J Dtsch Dermatol Ges. 2013;11 Suppl6:1-116
Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A.
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
J Clin Oncol. 2013;31(5):616-22
Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Heinzerling LM.
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.
PlOS One 2013;8(1):e53745
O'Day SJ, Eggermont AM, Chiarion-Sileni V, Kefford R, Grob JJ, Mortier L, Robert C, Schachter J, Testori A, Mackiewicz J, Friedlander P, Garbe C, Ugurel S, Collichio F, Guo W, Lufkin J, Bahcall S, Vukovic V, Hauschild A.
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma.
J Clin Oncol. 2013;31(9)_1211-8
Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R.
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
Lancet Oncol. 2013;14(3):249-56
Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D, Kim CC, McCormack CJ, Myskowski PL, Spleiss O, Trunzer K, Su F, Nelson B, Nolop KB, Grippo JF, Lee RJ, Klimek MJ, Troy JL, Joe AK
Analysis of dermatologic events in vemurafenib-treated patients with melanoma.
Oncologist 2013;18(3):314-22
Lacouture ME, Schadendorf D, Chu CY, Uttenreuther-Fischer M, Stammberger U, O'Brien D, Hauschild A.
Dermatologic adverse events associated with afatinib: an oral ErbB family blocker.
Expert Rev Anticancer Ther. 2013;13(6):721-8
Satzger I, Degen A, Asper H, Kapp A, Hauschild A, Gutzmer R.
Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy.
J Clin Oncol. 2013;31(13):3220-2
Hauschild A, Breuninger H, Kaufmann R, Kortmann RD, Klein M, Werner J, Reifenberger J, Dirschka T, Garbe C.
Brief S2k guidelines--Basal cell carcinoma of the skin.
J Dtsch Dermatol Ges. 2013;11 Suppl 3:10-5
Breuninger H, Eigentler T, Bootz F, Hauschild A, Kortmann RD, Wolff K, Stockfleth E, Szeimies RM, Rompel R, Garbe C, Grabbe S
Brief S2k guidelines--Cutaneous squamous cell carcinoma.
J Dtsch Dermatol Ges. 2013;11 Suppl 3:37-45
Ribas A, Hauschild A, Kefford R.
Reply to K.S. Wilson et al.
J Clin Oncol. 2013;31(22):2836-7
Satzger I, Degen A, Asper H, Kapp A, Hauschild A, Gutzmer R.
Reply to N. Rompoti et al.
J Clin Oncol. 2013;31(30):3845-6

2012

Egberts F, Kotthoff AM, Gerdes S, Egberts JH, Weichenthal M, Hauschild A
Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
Eur J Cancer 2012;48(5): 695-702
Hauschild A.
Photodynamic therapy for actinic keratoses: procedure matters?
Br J Dermatol 2012;166(1):3-5
Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N, Marincola FM.
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".
J Transl Med 2012; Jul 4;10:83
Eisemann N, Jansen L, Holleczek B, Waldmann A, Luttmann S, Emrich K, Hauschild A, Brenner H, Katalinic A; GEKID Survival Working Group.
Up-to-date results on survival of patients with melanoma in Germany.
Br J Dermatol 2012;167(3):606-12
Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, Carvajal RD, Egberts F, Hauschild A, Kashani-Sabet M, Goldinger SM, Dummer R, Long GV, McArthur G, Scherag A, Sucker A, Schadendorf D.
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.
J Clin Oncol 2012;30(19):2375-83
Weber JS, Kähler KC, Hauschild A.
Management of immune-related adverse events and kinetics of response with ipilimumab.
J Clin Oncol 2012;30(21):2691-7
Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A.
Efficacy and safety of vismodegib in advanced basal-cell carcinoma.
N Engl J Med 2012;366(23):2171-9
Homey B, Gerber PA, Wollenberg A, Dirschka T, Hassel JC, Bölke E, Hauschild A, Gutzmer R.
Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers.
J Dtsch Dermatol Ges 2012;10(8):559-63
Daud A, Soon C, Dummer R, Eggermont AM, Hwu WJ, Grob JJ, Garbe C, Hauschild A.
Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma.
Expert Opin Biol Ther 2012;12(8):1087-99
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Lancet 2012;380(9839):358-65
Leong SP, Mihm MC Jr, Murphy GF, Hoon DS, Kashani-Sabet M, Agarwala SS, Zager JS, Hauschild A, Sondak VK, Guild V, Kirkwood JM
Progression of cutaneous melanoma: implications for treatment.
Clin Exp Metastasis 2012;29(7):775-96
Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D.
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
Lancet Oncol 2012;13(11):1087-95
Eisemann N, Jansen L, Holleczek B, Waldmann A, Luttmann S, Emrich K, Hauschild A, Brenner H, Katalinic A; GEKID Survival Working Group.
Up-to-date results on survival of patients with melanoma in Germany.
Br J Dermatol 2012;167(3):606-12
Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G; ESMO Guidelines Working Group.
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol 2012;23 Suppl 7:vii86-91
Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, Grob JJ, Malvehy J, Newton-Bishop J, Stratigos A, Pehamberger H, Eggermont AM; European Dermatology Forum; European Association of Dermato-Oncology; European Organization of Research and Treatment of Cancer.
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012.
Eur J Cancer 2012;48(15):2375-90
Hauptmann N, Hauschild A, Schafer S, Kahler KC
Sustained complete Remission of metastatic malignant Melanoma with Ipilimumab
J Dtsch Dermatol Ges 2012;10(9):684-85

2011

Egberts F, Gutzmer R, Ugurel S, Becker JC, Trefzer U, Degen A, Schenck F, Frey L, Wilhelm T, Hassel JC, Schadendorf D, Livingstone E, Mauch C, Garbe C, Berking C, Rass K, Mohr P, Kaehler KC, Weichenthal M, Hauschild A.
Sorafenib and pegylated interferon-?2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial.
Ann Oncol 2011;22(7):1667-74
Ziefle S, Egberts F, Heinze S, Volkenandt M, Schmid-Wendtner M, Tilgen W, Linse R, Boettjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Heinz A, Hauschild A, Schaefer M.
Health-related quality of life before and during adjuvant interferon-? treatment for patients with malignant melanoma (DeCOG-trial).
J Immunother 2011;34(4):403-8
White RL Jr, Ayers GD, Stell VH, Ding S, Gershenwald JE, Salo JC, Pockaj BA, Essner R, Faries M, Charney KJ, Avisar E, Hauschild A, Egberts F, Averbook BJ, Garberoglio CA, Vetto JT, Ross MI, Chu D, Trisal V, Hoekstra H, Whitman E, Wanebo HJ, Debonis D, Vezeridis M, Chevinsky A, Kashani-Sabet M, Shyr Y, Berry L, Zhao Z, Soong SJ, Leong SP; Sentinel Lymph Node Working Group.
Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database.
Ann Surg oncol 2011;18(13):2593-600
Kähler KC, Egberts F, Hauschild A, Mohr P.
Adjuvant systemic treatment of melanoma
Hautarzt 2011;62(6):414, 416-22
Hauschild A, Egberts F, Garbe C, Bauer J, Grabbe S, Hamm H, Kerl H, Reusch M, Rompel R, Schlaeger M; expert group "Melanocytic nevi".
Melanocytic nevi.
J Dtsch Dermatol Ges 2011;9(9): 723-34
Papaspyrou G, Garbe C, Schadendorf D, Werner JA, Hauschild A, Egberts F.
Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors.
Melanoma Res 2011;21(6):475-82
Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT, Karthaus M, Riess H, Lipp HP, Hauschild A, Trarbach T, Wollenberg A.
Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.
Ann Oncol 2011;22(3):524-35
Satzger I, Meier A, Hoy L, Völker B, Kapp A, Hauschild A, Gutzmer R.
Sentinel node dissection delays recurrence and prolongs melanoma-related survival: an analysis of 673 patients from a single center with long-term follow-up.
Ann Surg Oncol 2011;18(2):514-20
Gutzmer R, Becker JC, Enk A, Garbe C, Hauschild A, Leverkus M, Reimer G, Treudler R, Tsianakas A, Ulrich C, Wollenberg A, Homey B.
Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician.
J Dtsch Dermatol Ges 2011;9(3): 195-203
Kähler KC, Hauschild A.
Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
J Dtsch Dermatol Ges 2011;8(4):277-86
Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM.
Systematic review of medical treatment in melanoma: current status and future prospects.
Oncologist 2011;16(1):5-24
Balagula Y, Garbe C, Myskowski PL, Hauschild A, Rapoport BL, Boers-Doets CB, Lacouture ME.
Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors.
Int J Dermatol 2011;50(2):129-46
Leong SP, Gershenwald JE, Soong SJ, Schadendorf D, Tarhini AA, Agarwala S, Hauschild A, Soon CW, Daud A, Kashani-Sabet M.
Cutaneous melanoma: a model to study cancer metastasis.
J Surg Oncol 2011;103(6):538-49
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
N Engl J Med 2011;364(26):2507-16
Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD.
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
N Engl J Meds 2011;364(20):2517-26
Egberts F, Hartje C, Schafmayer C, Kaehler KC, von Schönfels W, Hauschild A, Becker T, Egberts JH.
Risk evaluation in cutaneous melanoma patients undergoing lymph node dissection: impact of POSSUM.
Ann R Coll Surg Engl 2011;93(7):514-522
Hofmann MA, Hauschild A, Mohr P, Garbe C, Weichenthal M, Trefzer U, Drecoll U, Tilgen W, Schadendorf D, Kaatz M, Ulrich J.
Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial.
Melanoma Res 2011;21(6):516-23
Hauschild A, Kölbl O, Mackensen A, Schadendorf D.
[Forward].
Onkologie 2011;34 Suppl 2:1

2010

Heinze S, Egberts F, Rötzer S, Volkenandt M, Tilgen W, Linse R, Boettjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Hinzpeter A, Hauschild A, Schaefer M.
Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial.
J Immunother. 2010;33(1):106-14.
Schrama D, Thiemann A, Houben R, Kähler KC, Becker JC, Hauschild A.
Distinction of 2 different primary Merkel cell carcinomas in 1 patient by Merkel cell polyomavirus genome analysis.
Arch Dermatol. 2010;146(6):687-9
Egberts F, Momkvist A, Egberts JH, Kaehler KC, Hauschild A.
Serum S100B and LDH Are Not Useful in Predicting the Sentinel Node Status in Melanoma Patients.
Anticancer Res. 2010;30(5):1799-805.
Kirkwood JM, Lorigan P, Hersey P, Hauschild A, Robert C, McDermott D, Marshall MA, Gomez-Navarro J, Liang JQ, Bulanhagui CA
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.
Clin Cancer Res. 2010;16(3):1042-8
Wollenberg A, Kroth J, Hauschild A, Dirschka T.
Cutaneous side effects of EGFR inhibitors--appearance and management.
Dtsch Med Wochenschr. 2010;135(4):149-54
Hauschild A, Weichenthal M, Rass K, Linse R, Berking C, Böttjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Stein A, Näher H, Schadendorf D, Mohr P, Kaatz M, Tronnier M, Hein R, Schuler G, Egberts F, Garbe C.
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.
J Clin Oncol. 2010;28(5):841-6
Dummer R, Hauschild A, Guggenheim M, Jost L, Pentheroudakis G; ESMO Guidelines Working Group.
Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2010;21 Suppl 5:v194-7
Kähler KC, Egberts F, Hauschild A.
Current aspects of adjuvant therapy of malignant melanoma.
Hautarzt 2010;61(6):523-31; quiz 532-3
Kaehler KC, Egberts F, Hauschild A.
Electrochemotherapy in symptomatic melanoma skin metastases: intraindividual comparison with conventional surgery.
Dermatol Surg. 2010;36(7):1200-2
Egberts F, Momkvist A, Egberts JH, Kaehler KC, Weichenthal M, Hauschild A.
Clinicopathologic prognostic markers of survival: an analysis of 259 patients with malignant melanoma >or=1 mm.
Tumour Biol. 2010;31(1):8-15.
Kaehler KC, Sondak VK, Schadendorf D, Hauschild A.
Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma.
Eur J Cancer 2010;46(1):41-6
Kähler KC, Hauschild A.
Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
J Dtsch Dermatol Ges. 2010;im Druck
Mikhaimer NC, Kähler KC, Schwarz T, Mundhenke C, Hauschild A.
Giant basal cell carcinoma of the breast mimicking paget's disease: complete remission after photodynamic therapy.
Onkologie. 2010;33(11):613-5.
Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A, Schadendorf D.
Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
Semin Oncol. 2010;37(5):485-98
Livingstone E, Caliebe A, Egberts F, Proksch E, Buiting K, Schubert C, Claviez A, Siebert R, Hauschild A.
Malignant melanoma and Wiedemann-Beckwith syndrome in childhood.
Klin Pediatr 2010;222(6):388-90
Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, Grob JJ, Malvehy J, Newton-Bishop J, Stratigos A, Pehamberger H, Eggermont A
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline.
Eur J Cancer 2010;46(2):270-83
Loser K, Brzoska T, Oji V, Auriemma M, Voskort M, Kupas V, Klenner L, Mensing C, Hauschild A, Beissert S, Luger TA.
The neuropeptide alpha-melanocyte-stimulating hormone is critically involved in the development of cytotoxic CD8+ T cells in mice and humans.
PLoS One 2010;5(2):e8958
Scherer D, Rachakonda PS, Angelini S, Mehnert F, Sucker A, Egberts F, Hauschild A, Hemminki K, Schadendorf D, Kumar R.
Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors.
J Invest Dermatol 2010;130(12):2844-2848
Friebe A, Horn M, Schmidt F, Janssen G, Schmid-Wendtner MH, Volkenandt M, Hauschild A, Goldsmith CH, Schaefer M.
Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma.
Psychosomatics 2010;51(6):466-473
Kähler KC, Mustoph D, Hauschild A
Aktuelle Aspekte der Therapie von Pavasaten in der Dermatoonkologie
in: Szeimies R, Hauschild A, Garbe C, Kaufmann R, Landthaler M: Tumoren der Haut; Stuttgart, Georg Thieme Verlag 2010;pp 223 - 234
Hauschild A, Kähler KC, Volkenandt M
Adjuvante Therapie des Melanoms
in: Szeimies R, Hauschild A, Garbe C, Kaufmann R, Landthaler M: Tumoren der Haut; Stuttgart, Georg Thieme Verlag 2010;pp 375 - 18

2009

Agarwala SS, Becker JC, Eggermont AM, Flaherty KT, Garbe C, Goldstein AM, Halpern A, Kashani-Sabet M, Hauschild A, Kirkwood JM, Leachman S, Lorigan P, McMahon M, Messina J, Ribas A, Samlowski WE, Schadendorf D, Sondak VK.
Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008
Pigment Cell Melanoma Res. 2009;22(5):532-43
Livingstone E, Hauschild A.
Reply to Y. Khakoo et al.
J Clin Oncol. 2009;im Druck
Hauschild A, Schadendorf D
In process citation
J Dtsch Dermatol Ges. 2009;7(8):726-7.
Mohr P, Hauschild A, Trefzer U, Weichenthal M.
Quality of life in patients receiving high-dose interferon alfa-2b after resected high-risk melanoma.
J Clin Oncol. 2009;27(24):e70
Hauschild A, Weichenthal M, Rass K, Linse R, Ulrich J, Stadler R, Volkenandt M, Grabbe S, Proske U, Schadendorf D, Brockmeyer N, Vogt T, Rompel R, Kaufmann R, Kaatz M, Näher H, Mohr P, Eigentler T, Livingstone E, Garbe C.
Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.
J Clin Oncol. 2009;27(21):3496-502
Kaehler KC, Sondak VK, Schadendorf D, Hauschild A
Pegylated interferons: Prospects for the use in the adjuvant and palliative therapy of metastatic melanoma.
Eur J Cancer 2009;im Druck
Kaehler KC, Egberts F, Lorigan P, Hauschild A.
Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient.
Melanoma Res. 2009;19(5):333-4.
Kähler KC, Hauschild A.
Skin changes as a result of targeted therapies in oncology patients: cutaneous side effects of targeted therapies in oncology patients
Hautarzt 2009;60(5):433-40
Kähler KC, Mustroph D, Hauschild A
Current recommendations for prevention and therapy of extravasation reactions in dermato-oncology.
J Dtsch Dermatol Ges. 2009;7(1):21-8.
Egberts F, Hitschler WN, Weichenthal M, Hauschild A
Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse
Melanoma Res. 2009;19(1):31-5
Dummer R, Hauschild A, Pentheroudakis G
Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up
Ann Oncol 2009;20 Suppl 4:129-31.
MacKie RM, Hauschild A, Eggermont AM
Epidemiology of invasive cutaneous melanoma
Ann Oncol. 2009;20 Suppl 6:vi1-7
Mohr P, Eggermont AM, Hauschild A, Buzaid A
Staging of cutaneous melanoma
Ann Oncol. 2009;20 Suppl 6:vi14-21
Testori A, Rutkowski P, Marsden J, Bastholt L, Chiarion-Sileni V, Hauschild A, Eggermont AM
Surgery and radiotherapy in the treatment of cutaneous melanoma
Ann Oncol. 2009;20 Suppl 6:vi22-9
Eggermont AM, Testori A, Marsden J, Hersey P, Quirt I, Petrella T, Gogas H, MacKie RM, Hauschild A
Utility of adjuvant systemic therapy in melanoma
Ann Oncol. 2009;20 Suppl 6:vi30-4
Hersey P, Bastholt L, Chiarion-Sileni V, Cinat G, Dummer R, Eggermont AM, Espinosa E, Hauschild A, Quirt I, Robert C, Schadendorf D
Small molecules and targeted therapies in distant metastatic disease
Ann Oncol. 2009;20 Suppl 6:vi35-40
Schadendorf D, Algarra SM, Bastholt L, Cinat G, Dreno B, Eggermont AM, Espinosa E, Guo J, Hauschild A, Petrella T, Schachter J, Hersey P
Immunotherapy of distant metastatic disease
Ann Oncol. 2009;20 Suppl 6:vi41-50
Gogas H, Eggermont AM, Hauschild A, Hersey P, Mohr P, Schadendorf D, Spatz A, Dummer R
Biomarkers in melanoma
Ann Oncol. 2009;20 Suppl 6:vi8-13
Hauschild A, Schadendorf D
Working group of the Dermatologic Oncology
J Dtsch Dermatol Ges. 2009;7(8):726-7
Szeimies RM, Stockfleth E, Popp G, Borrosch F, Brüning H, Dominicus R, Mensing H, Reinhold U, Reich K, Moor AC, Stocker M, Ortland C, Brunnert M, Hauschild A
Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data
Br J Dermatol 2009;Epub Jun 30 Ahead of Print
Kashani-Sabet M, Venna S, Nosrati M, Rangel J, Sucker A, Egberts F, Baehner FL, Simko J, Leong SP, Haqq C, Hauschild A, Schadendorf D, Miller JR 3rd, Sagebiel RW
A multimarker prognostic assay for primary cutaneous melanoma
Clin Cancer Res 2009;15(22):6987-92
Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, Grob JJ, Malvehy J, Newton-Bishop J, Stratigos A, Pehamberger H, Eggermont A
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline
Eur J Cancer 2009;33(1):106-14
Mensing C, Eiling E, Schwarz T, Hauschild A
Eczematous malignant melanoma: a wolf in Sheep's clothing
Onkologie 2009;32:206-208

2008

Garbe C, Schadendorf D, Stolz W, Volkenandt M, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R, Hauschild A
Short German guidelines: malignant melanoma.
J Dtsch Dermatol Ges. 2008;6 Suppl 1:S9-S14
Breuninger H, Bootz F, Hauschild A, Kortmann RD, Wolff K, Stockfleth E, Szeimies M, Rompel R, Garbe C
Short German guidelines: squamous cell carcinoma.
J Dtsch Dermatol Ges. 2008;6 Suppl 1:S5-8
Hauschild A, Breuninger H, Kaufmann R, Kortmann RD, Schwipper V, Werner J, Reifenberger J, Dirschka T, Garbe C.
Short German guidelines: basal cell carcinoma
J Dtsch Dermatol Ges. 2008;6 Suppl 1:S2-4
Becker J, Mauch C, Kortmann RD, Keilholz U, Bootz F, Garbe C, Hauschild A, Moll I.
Short German guidelines: Merkel cell carcinoma
J Dtsch Dermatol Ges. 2008;6 Suppl 1:S15-6
Eiling E, Brandt M, Schwarz T, Hauschild A.
Pimecrolimus: a novel treatment for cetuximab-induced papulopustular eruption.
Arch Dermatol 2008;144(9):1236-8.
Eigentler TK, Radny P, Hauschild A, Gutzmer R, Linse R, Pföhler C, Wagner SN, Schadendorf D, Ellwanger U, Garbe C; German Dermatologic Cooperative Oncology Group
Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group
Melanoma Res. 2008;18(5):353-8
Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP.
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Oncologist 2008;13(9):1001-11
Schrama D, Hauschild A, Becker JC.
Immunmodulatory antibodies in the treatment of skin cancer
Hautarzt 2008;59(10):806-13
Hauschild A, Trefzer U, Garbe C, Kaehler KC, Ugurel S, Kiecker F, Eigentler T, Krissel H, Schott A, Schadendorf D.
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
Melanoma Res 2008;18(4):274-8
Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U; EORTC Melanoma Group.
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
Lancet 2008;372(9633):117-26
Hauschild A, Dummer R, Ugurel S, Kaehler KC, Egberts F, Fink W, Both-Skalsky J, Laetsch B, Schadendorf D.
Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.
Cancer 2008;113(6):1404-11
Egberts F, Kahler KC, Livingstone E, Hauschild A.
Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
Onkologie 2008;31(7):398-403
Egberts F, Pollex A, Egberts JH, Kaehler KC, Weichenthal M, Hauschild A.
Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH.
Onkologie 2008;31(7):380-4.
Mohr EB, Lohmeyer JA, Mikhaimer NC, Mailänder P, Schwarz T, Hauschild A.
Multiple squamous cell carcinomas in junctional epidermolysis bullosa: a surgical challenge
Dermatol Surg 2008;34(8):1131-6.
Hauschild A, Rass K, Tilgen W.
Systemic treatment of melanoma. Current clinical trials
Hautarzt 2008;59(6):484-91
Dummer R, Hauschild A, Jost L; ESMO Guidelines Working Group
Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Ann Oncol 2008;19 Suppl 2:ii86-8.
Egberts F, Kaehler KC, Brasch J, Schwarz T, Cerroni L, Hauschild A.
Multiple skin metastases of malignant melanoma with unusual clinical and histopathologic features in an immunosuppressed patient.
J Am Acad Dermatol 2008;58(5):880-4
Kaehler KC, Russo PA, Egberts F, Warnke PH, Cerroni L, Hauschild A.
Metastatic melanoma of the tongue arising from oral melanosis.
Arch Dermatol 2008;144(4):558-60
Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R.
Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting.
Melanoma Res 2008;18(2):152-60
von Moos R, Thuerlimann BJ, Aapro M, Rayson D, Harrold K, Sehouli J, Scotte F, Lorusso D, Dummer R, Lacouture ME, Lademann J, Hauschild A.
Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.
Eur J Cancer 2008;44(6):781-90
Lorigan P, Eisen T, Hauschild A.
Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?
Exp Dermatol 2008;17(5):383-94
Garbe C, Radny P, Linse R, Dummer R, Gutzmer R, Ulrich J, Stadler R, Weichenthal M, Eigentler T, Ellwanger U, Hauschild A
Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis.
Ann Oncol 2008;19(6):1195-201
Dummer R, Hauschild A, Becker JC, Grob JJ, Schadendorf D, Tebbs V, Skalsky J, Kaehler KC, Moosbauer S, Clark R, Meng TC, Urosevic M.
An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma.
Clin Cancer Res 2008;14(3):856-64
Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dréno B, Kirkwood JM.
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.
Cancer 2008;112(5):982-94
Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R.
Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma.
Melanoma Res 2008;18(1):61-7
Spieth K, Kaufmann R, Dummer R, Garbe C, Becker JC, Hauschild A, Tilgen W, Ugurel S, Beyeler M, Bröcker EB, Kaehler KC, Pföhler C, Gille J, Leiter U, Schadendorf D.
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Ann Oncol 2008;19(4):801-6
Krengel S, Breuninger H, Hauschild A, Höger P, Merl V, Hamm H.
Installation of a network for patients with congenital melanocytic nevi in German-speaking countries.
J Dtsch Dermatol Ges 2008;6(3):204-8
Kähler KC, Mustroph D, Hauschild A
Current recommendations for prevention and therapy of extravasation reactions in dermato-oncology.
J Dtsch Dermatol Ges. 2008;7(1):21-8
Hauschild A, Kähler KC, Schäfer M, Fluck M
Interdisciplinary management recommendations for toxicity associated with interferon-alfa therapy.
J Dtsch Dermatol Ges. 2008;6(10):829-37, 829-38
Kaehler KC, Russo PA, Katenkamp D, Kreusch T, Neuber K, Schwarz T, Hauschild A.
Melanocytic schwannoma of the cutaneous and subcutaneous tissues: three cases and a review of the literature.
Melanoma Res 2008;18(6):438-42
Hauschild A, Kähler KC, Egberts F, Pehamberger H, Schlag PM
Malignes Melanom.
In: Chirurgische Onkologie. Michael Gnant, Peter M. Schlag (Hrsg.), Springer Verlag Wien 2008;449-465

2007

Egberts F, Egberts JH, Schwarz T, Hauschild A
Kissing melanoma or kissing nevus of the penis?
Urology 2007;69:384.e5-e7
Hauschild A
Clinical studies with sorafenib (Nexavar) in metastatic melanoma.
J Dtsch Dermatol Ges. 2007;5(4): 345
Siegel R, Hauschild A, Kettelhack C, Kähler KC, Bembenek A, Schlag PM.
Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma.
Eur J Surg Oncol. 2007;33(5): 627-32
Middleton M, Hauschild A, Thomson D, Anderson R, Burdette-Radoux S, Gehlsen K, Hellstrand K, Naredi P.
Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.
Ann Oncol 2007;18(10):1691-7.
Hauschild A, Szeimies RM.
EADV-Conference 16.-20.05.2007 in Vienna: Study of new pharmaceuticals 5-ALAPlaster (PD P 506 A)]]
J Dtsch Dermatol Ges 2007;5(9):815
Satzger I, Meier A, Schenck F, Kapp A, Hauschild A, Gutzmer R.
Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.
Int J Cancer 2007;121(11):2562-6
Dummer R, Assaf C, Bagot M, Gniadecki R, Hauschild A, Knobler R, Ranki A, Stadler R, Whittaker S.
Maintenance therapy in cutaneous T-cell lymphoma: Who, when, what?
Eur J Cancer. 2007;43(16):2321-9.
Hauschild A, Schadendorf D, Garbe C, Ugurel S, Kähler KC.
New promises in the adjuvant, and palliative treatment of melanoma.
Cancer Treat Res. 2007;135:277-92
Beckmann MW, Adler G, Albers P, Bruns J, Ehninger G, Hauschild A, Schlag P, Schmiegel W, Schmitz S, Wiegel T, Bamberg M
Dreistufenmodell optimiert Behandlung unter Kostendeckung.
Deutsches Ärzteblatt 2007;104: B2644-B2647
Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R.
Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma.
Melanoma Res 2007;17(6):393-9
Hauschild A, Kähler KC
Adjuvante Interferon-Therapie bei Hochrisiko-Melanomen.
Best practice oncology 2007;Heft 2
Hauschild A, Egberts F, Pehamberger H
Chirurgische Therapie des malignen Melanoms
In: Gnant, M; Schlag, PM (Hrsg.): Tumorchirurgie. Strategien und Standards für die Praxis. Springer Verlag, Wien 2007;

2006

Dummer R, Hauschild A, Skalsky J, Burg G, Weichenthal M.
Bexarotene and systemic disease progression in CTCL?
J Am Acad Dermatol 2006;55:365-366
Becker JC, Kirkwood JM, Agarwala SS, Dummer R, Schrama D, Hauschild A.
Molecularly targeted therapy for melanoma: current reality and future options
Cancer 2006;107: 2317-2327
Warnke PH, Schimmelpenning GW, Happle R, Springer IN, Hauschild A, Wiltfang J, Acil Y, Sherry E, Proksch E, Luettges J, Russo PA.
Intraoral lesions associated with sebaceous nevus syndrome
J Cutan Pathol 2006;33:175-180
Schadendorf D, Hauschild A, Ugurel S, Thoelke A, Egberts F, Kreissig M, Linse R, Trefzer U, Vogt T, Tilgen W, Mohr P, Garbe C
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Ann Oncol  2006;17:1592-1597
Ugurel S, Schadendorf D, Pfohler C, Neuber K, Thoelke A, Ulrich J, Hauschild A, Spieth K, Kaatz M, Rittgen W, Delorme S, Tilgen W, Reinhold U; Dermatologic Cooperative Oncology Group
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Clin Cancer Res 2006;12:5258-5259
Egberts F, Lischner S, Russo P, Kampen WU, Hauschild A
Diagnostic and therapeutic procedures for management of melanoma during pregnancy: risks for the fetus?
J Dtsch Dermatol Ges. 2006;4:717-720
Hauschild A, Garbe C, Bauer J, Hamm H, Kerl H, Reusch M, Rompel R, Schlaeger M; weitere Mitglieder der Expertengruppe "melanozytare Navi".
Melanozytäre Nävi
J Dtsch Dermatol Ges.  2006;4:686-697
Hauschild A, Kleeberg UR
Adjuvant therapy of melanoma : From non-specific immune stimulants into the future.
Hautarzt 2006;57:764-772
Krengel S, Hauschild A, Schafer T.
Melanoma risk in congenital melanocytic naevi: a systematic review.
Br J Dermatol. 2006;155:1-8
Hauschild A, Egberts F, Russo P, Kaehler KC.
Individualized therapy of disseminated cancer using malignant melanoma as a model.
Cancer Metastasis Rev. 2006;25:253-256
Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R.
Brief guidelines: malignant melanoma of the skin]
J Dtsch Dermatol Ges.  2006;4:344-349
Hauschild A, Kahler KC, Egberts F
Modern treatment modalities in actinic keratoses of the skin
Dtsch Med Wochenschr 2006;131:447-452
Hauschild A, Garbe C
Brief guideline--cutaneous neuroendocrine carcinoma (Merkel cell carcinoma)
J Dtsch Dermatol Ges. 2006;4:508-510
Weller K, Vetter-Kauzock C, Kähler K, Hauschild A, Eigentler T, Pföhler C, Neuber K, Moll I, Krause M, Kneisel L, Nashan D, Thoelke A, Letsch B, Näher H, Becker JC
Umsetzung von Leitlinien bei seltenen Erkrankungen am Beispiel des Merkelzellkarzinoms.
Ärzteblatt 2006;42: A-2791/B-2426/C-2334
Hauschild A, Egberts F, Kaufmann R
Operative Therapie des primären Melanoms
in: Garbe, C. (Hrsg.): Onkologie aktuell. Springer, Berlin 2006;197-205

2005

Hoffmann C, Horst HA, Weichenthal M, Hauschild A
Malignant melanoma and HIV infection -- aggressive course despite immune reconstitution
ONKOLOGIE 2005;28:35-37
Hauschild A, Lischner S, Lange-Asschenfeldt B, Egberts F.
Treatment of actinic cheilitis using photodynamic therapy with methylaminolevulinate: report of three cases.
DERMATOLOGIC SURGERY  2005;31:1344-1347
Kaehler KC, Lange-Asschenfeldt B, Proksch E, Hauschild A.
Giant naevoid syringocystadenoma papilliferum.
ACTA DERMATO-VENEREOLOGICA 2005;85:453-454
Dadras SS, Lange-Asschenfeldt B, Velasco P, Nguyen L, Vora A, Muzikansky A, Jahnke K, Hauschild A, Hirakawa S, Mihm MC, Detmar M.
Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes.
MODERN PATHOLOGY  2005;18:1232-1242
Wolf C, Haacke TC, Hoft S, Peters K, Hauschild A.
Malignant melanoma of the uvula and soft palate.
HAUTARZT 2005;56:156-159
Jensen JM, Egberts F, Proksch E, Hauschild A
Disseminated porokeratosis palmaris and plantaris treated with imiquimod cream to prevent malignancy.
Acta Derm Venereol 2005;85(6):550-1
Hauschid A, Kähler KC, Lischner S
Adjuvante und palliative systemische Therapie des Melanoms.
In: Fortschritte der praktischen Dermatologie. Plewig G, Kaudewitz P, Sander C (Hrsg.), Springer Verlag 2005;

2004

Thoelke A, Willrodt S, Hauschild A, Schadendorf D
Primary extracutaneous malignant melanoma: a comprehensive review with emphasisn on treatment
ONKOLOGIE 2004;27:492-499
Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saiag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study
JOURNAL OF CLINICAL ONCOLOGY 2004;22:1118-1125
Volkenandt M, Hauschild A, Garbe C
Adjuvante medikamentöse Therapie des malignen Melanoms.
Onkologe 2004;10:710-716
Hauschild A, Lischner S, Kähler K
Malignes Melanom – operative Therapie des Primärtumors.
Onkologe 2004;10:701-709
Lischner S, Kähler K, Hauschild A
Symposiumsbericht "14. Kieler Symposium für Dermato-Onkologie und Operative Dermatologie"
Forum DKG 1 2004;56-60
Hauschild A, Frick S
Adjuvante Therapie des Melanoms mit Zytokinen
In: Schadendorf D (Hrsg.) Aktuelle Aspekte der Immuntherapie in der Dermatologie. Uni-Med Verlag, 2004;
Hauschild A, Garbe C
Kurzgefasste Interdisziplinäre Leitlinien 2004
In: Qualitätssicherung in der Onkologie. Diagnostik und Therapie maligner Erkrankungen. Hrsg.: Deutsche Krebsgesellschaft e.V. W. Zuckschwerdt Verlag, 2004;

2003

Zimpfer-Rechner C, Hofmann U, Figl R, Becker JC, Trefzer U, Keller I, Hauschild A, Schadendorf D
Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG).
MELANOMA RESEARCH  2003;13:531-536
Wollina U, Dummer R, Brockmeyer NH, Konrad H, Busch JO, Kaatz M, Knopf B, Koch HJ, Hauschild A
Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma.
CANCER 2003;98:993-1001
Warnke PH, Hauschild A, Schimmelpenning GW, Terheyden H, Sherry E, Springer IN
The sebaceous nevus as part of the Schimmelpenning-Feuerstein-Mims Syndrome--an obvious phacomatosis first documented in 1927.
JOURNAL OF CUTANEOUS PATHOLOGY  2003;30:470-472
Schmook T, Stockfleth E, Lischner S, Gahn B, Christophers E, Hauschild A
Remarkable remission of a follicular lymphoma treated with rituximab and polychemotherapy (CHOP).
CLINICAL AND EXPERIMENTAL DERMATOLOGY  2003;28:31-33
Rosien F, Haacke TC, Hauschild A
Amelanotic malignant melanoma of the scalp clinically resembling a proliferating trichilemmal cyst
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT  2003;128:2360-2362
Oratz R, Hauschild A, Sebastian G, Schadendorf D, Castro D, Brocker EB, Orenberg EK
Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma.
MELANOMA RESEARCH  2003;13:59-66
Neuber K, Reinhold U, Deutschmann A, Pfohler C, Mohr P, Pichlmeier U, Baumgart J, Hauschild A
Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial.
MELANOMA RESEARCH  2003;13:81-85
Hauschild A, Weichenthal M, Balda BR, Becker JC, Wolff HH, Tilgen W, Schulte KW, Ring J, Schadendorf D, Lischner S, Burg G, Dummer
Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.
JOURNAL OF CLINICAL ONCOLOGY  2003;21:2883-2888
Mohr P, Weichenthal M, Hauschild A
Adjuvant therapy in melanoma
ONKOLOGIE 2003;26:227-233
Mornex F, Thomas L, Mohr P, Hauschild A, Delaunay MM, Lesimple T, Tilgen W, Bui BN, Guillot B, Ulrich J, Bourdin S, Mousseau M, Cupissol D, Bonneterre ME, De Gislain C, Bensadoun RJ, Clavel M
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma.
MELANOMA RESEARCH  2003;13:97-103
Mornex F, Thomas L, Mohr P, Hauschild A, Delaunay MM, Lesimple T, Tilgen W, Nguyen BB, Guillot B, Ulrich J, Bourdin S, Mousseau M, Cupissol D, Bonneterre J, de Gislain C, Bensadoun JR, Clavel M
Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma
Cancer Radiother  2003;7:1-8
Hauschild A
Meeting report of the 39th Annual Conference of the American Society of Clinical Oncology (ASCO), 5/31-6/3/2003, Chicago, USA].
HAUTARZT 2003;54:999-1002
Hauschild A, Rosien F, Lischner S
Surgical standards in the primary care of melanoma patients.
ONKOLOGIE 2003;26:218-222
Hauschild A, Christophers E
Melanom.
In: Onkologische Therapie. Hrsg.: Bruhn D, Fölsch UR, Kneba M, Löffler H. Schattauer, Stuttgart. 2003;
Hauschild A, Garbe C
Kutanes neuroendokrines Karzinom (Merkel-Zellkarzinom).
In: Dermatologische Qualitätssicherung: Leitlinien und Empfehlungen. Hrsg.: Korting HC, Callies R, Reusch M, Schlaeger M, Sterry W. Zuckschwerdt Verlag, München. 2003;
Hauschild A, Gläser R
Malignes Melanom.
In: Klinikleitfaden Dermatologie, 2. Auflage, Urban und Fischer (München). 2003;

2002

Eiling, S., Lischner, S., Rosien, F., Haacke, T.C., Schafer, F., Christophers, E., Hauschild, A.
Temozolomid als Therapieoption bei fernmetastasierten Melanompatienten mit ungünstiger Prognose.
HAUTARZT 2002;53:659-665
Lischner, S., Rosien, F., Eiling, S., Haacke, T.C., Hauschild, A.
Das Lipom der Lippe.
HAUTARZT 2002;53:400-402
Meyer, T., Hauschild, A., Kromminga, A., Hartlepp, J., Arndt, R., Christophers, E., Stockfleth, E.
Clinical evaluation of 5-S-Cysteinyldopa testing using a new and optimized detection system as a tumour marker for malignant melanoma.
MELANOMA RESEARCH 2002;12:471-477
Schadendorf, D., Schadendorf, C., Hauschild, A.
The use oft histamine in cancer immunotherapy.
JOURNAL OF INVESTIGATIVE DERMATOLOGY  2002;118:560-561
Stockfleth, E., Ulrich, C., Hauschild, A., Lischner, S, Meyer, T., Christophers, E.
Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod. A report of 3 cases.
EUROPEAN JOURNAL OF DERMATOLOGY 2002;12:569-572
Eiling, S., Lischner, S., Busch, J.O., Rothaupt, D., Christophers, E., Hauschild, A.
Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin.
BRITISH JOURNAL OF DERMATOLOGY 2002;147:150-153
Moehrle, M., Lischner, S., Dunsche, A., Breuninger, H., Hauschild, A.
Cerebriform giant melanocytic nevus of the scalp: report of two cases with different surgical approaches.
DERMATOLOGIC SURGERY 2002;28:75-79
Frick S, Lischner S, Rosien F, Haacke TC, Schafer F, Christophers E, Hauschild A
Temozolomid als Therapieoption bei Patienten mit fernmetastasiertem Melanom und ungünstiger Prognose
Hautarzt 2002;53(10):659-65
Hauschild, A., Garbe, C.
Kutanes neuroendokrines Karzinom (Merkel-Zellkarzinom).
In: Qalitätssicherung in der Onkologie. Diagnostik und Therapie maligner Erkrankungen. Kurzgefaßte interdisziplinäre Leitlinien. Zuckschwerdt Verlag, München. 2002;
Hauschild, A., Eiling, S.
Ethische Aspekte randomisierter Therapiestudien.
In: Wolff, H.H., Welzel, J., von Engelhardt, D. (Hrsg.): Ethik in der Dermato-Venerologie. Hansisches Verlagskontor (Lübeck). 2002;

Zurück

Aktuelles:

 

Praktikum der Dermatologie

Das Hauptpraktikum Dermatologie beginnt am 17.10.2017 um 7:45 mit einer Einführungsvorlesung im Hörsaal der Hautklinik.  [mehr]

 


Dermatologie für Zahnmediziner

Die Veranstaltung beginnt am 24.10.2017  um 10:00 c.t. im Hörsaal der Hautklinik.


Lehrpreis 2017

Der Preis der Medizinischen Fakultät für die beste Lehre geht in diesem Jahr erneut an die Hautklinik  [mehr]


Neurodermitis Präventionsstudie

Studie zur frühkindlichen Anwendung von Hautpflegecremes [mehr]


Regulation von Botenstoffen der Entzündung

Kieler Team des Exzellenzclusters Entzündungsforschung deckt grundlegend neuen Mechanismus au. [mehr]


Prof. Fölster-Holst neue Präsidentin der ESPD

Professorin Dr. Regina Fölster-Holst, Klinik für Dermatologie, Venerologie und Allergologie, Medizinische Fakultät der Christian-Albrechts-Universität zu Kiel ist neue Präsidentin der Europäischen Gesellschaft für Kinderdermatologie (European Society for Pediatric Dermatology, ESPD). [mehr]


Patientenleitlinie zum Melanom erschienen

Der umfangreiche Ratgeber gibt in allgemeinverständlicher Sprache alle Empfehlungen zu Untersuchungen und Behandlungen wieder, die zuvor für die ärztliche Leitlinie zum Melanom erarbeitet worden sind.

Die Druckfassung zum kostenlosen Download [hier]   

 

Die Seite wurde zuletzt am 16.11.2017 um 11:51 geändert.